PE20140198A1 - Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima - Google Patents
Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzimaInfo
- Publication number
- PE20140198A1 PE20140198A1 PE2013001496A PE2013001496A PE20140198A1 PE 20140198 A1 PE20140198 A1 PE 20140198A1 PE 2013001496 A PE2013001496 A PE 2013001496A PE 2013001496 A PE2013001496 A PE 2013001496A PE 20140198 A1 PE20140198 A1 PE 20140198A1
- Authority
- PE
- Peru
- Prior art keywords
- amidobenzyl
- dipeptide
- linked
- coupling
- binder
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 230000008878 coupling Effects 0.000 abstract 3
- 238000010168 coupling process Methods 0.000 abstract 3
- 238000005859 coupling reaction Methods 0.000 abstract 3
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- OVHQWOXKMOVDJP-UHFFFAOYSA-N melitin Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(OC=2C=C3C(C(C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)=C(C=4C=CC(O)=CC=4)O3)=O)=C(O)C=2)OC(C)C1O OVHQWOXKMOVDJP-UHFFFAOYSA-N 0.000 abstract 2
- 229920000768 polyamine Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 206010073069 Hepatic cancer Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 abstract 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 150000003141 primary amines Chemical class 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427936P | 2010-12-29 | 2010-12-29 | |
| US13/336,028 US8426554B2 (en) | 2010-12-29 | 2011-12-23 | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140198A1 true PE20140198A1 (es) | 2014-02-21 |
Family
ID=46383848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001496A PE20140198A1 (es) | 2010-12-29 | 2011-12-28 | Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2658579A4 (enExample) |
| JP (1) | JP5941926B2 (enExample) |
| KR (1) | KR20130136494A (enExample) |
| CN (1) | CN103491982B (enExample) |
| AU (1) | AU2011352204B2 (enExample) |
| BR (1) | BR112013014115A2 (enExample) |
| CA (1) | CA2816041C (enExample) |
| CL (2) | CL2013001876A1 (enExample) |
| MX (2) | MX347298B (enExample) |
| NZ (1) | NZ611656A (enExample) |
| PE (1) | PE20140198A1 (enExample) |
| RU (1) | RU2619453C2 (enExample) |
| SG (1) | SG189942A1 (enExample) |
| WO (1) | WO2012092373A2 (enExample) |
| ZA (1) | ZA201302896B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2015021092A1 (en) * | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| KR102775461B1 (ko) * | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| EP3630742B1 (en) * | 2017-05-24 | 2023-08-16 | Ramot at Tel-Aviv University Ltd. | Chemiluminescent probes for imaging/detection of proteases |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| AU2019416109A1 (en) * | 2018-12-28 | 2021-07-22 | Sirnaomics, Inc. | Targeted delivery of therapeutic molecules |
| CN114450326B (zh) * | 2019-06-24 | 2025-02-11 | 普罗美加公司 | 用于将生物分子递送到细胞中的改性聚胺聚合物 |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| CN115209922A (zh) * | 2021-01-28 | 2022-10-18 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| KR20240024104A (ko) * | 2021-06-24 | 2024-02-23 | 가부시키가이샤 토호쿠 테크노 아치 | 형광 프로브 |
| KR102712976B1 (ko) * | 2021-07-27 | 2024-10-07 | 국립안동대학교 산학협력단 | 등검은말벌 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
| CN113621003B (zh) * | 2021-09-10 | 2023-02-03 | 国科温州研究院(温州生物材料与工程研究所) | 一种制备有机分子共价修饰的功能化核酸材料的方法及其应用 |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| CN121079108A (zh) * | 2023-05-12 | 2025-12-05 | 五稜化药株式会社 | 冻结干燥制剂、冻结干燥溶液和这些的制造方法、以及液剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| EP1242609A2 (en) * | 1999-12-30 | 2002-09-25 | Novartis AG | Novel colloid synthetic vectors for gene therapy |
| HUP0300024A2 (en) * | 2000-02-24 | 2003-05-28 | Genentech Inc | Caspase activated prodrugs therapy |
| EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
| WO2007059404A2 (en) * | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| CN101500548A (zh) * | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| RU2430740C2 (ru) * | 2006-08-18 | 2011-10-10 | Ф.Хоффманн-Ля Рош Аг | Поликонъюгаты для введения in vivo полинуклеотидов |
| TW201004647A (en) * | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
-
2011
- 2011-12-28 MX MX2016006733A patent/MX347298B/es unknown
- 2011-12-28 NZ NZ611656A patent/NZ611656A/en not_active IP Right Cessation
- 2011-12-28 SG SG2013029830A patent/SG189942A1/en unknown
- 2011-12-28 CN CN201180061179.6A patent/CN103491982B/zh active Active
- 2011-12-28 BR BR112013014115A patent/BR112013014115A2/pt not_active IP Right Cessation
- 2011-12-28 EP EP11853858.6A patent/EP2658579A4/en not_active Withdrawn
- 2011-12-28 WO PCT/US2011/067588 patent/WO2012092373A2/en not_active Ceased
- 2011-12-28 MX MX2013007316A patent/MX341118B/es active IP Right Grant
- 2011-12-28 CA CA2816041A patent/CA2816041C/en active Active
- 2011-12-28 RU RU2013117286A patent/RU2619453C2/ru active
- 2011-12-28 PE PE2013001496A patent/PE20140198A1/es not_active Application Discontinuation
- 2011-12-28 KR KR1020137017195A patent/KR20130136494A/ko not_active Ceased
- 2011-12-28 JP JP2013547648A patent/JP5941926B2/ja not_active Expired - Fee Related
- 2011-12-28 AU AU2011352204A patent/AU2011352204B2/en not_active Ceased
-
2013
- 2013-04-22 ZA ZA2013/02896A patent/ZA201302896B/en unknown
- 2013-06-25 CL CL2013001876A patent/CL2013001876A1/es unknown
-
2015
- 2015-12-10 CL CL2015003580A patent/CL2015003580A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013117286A (ru) | 2015-03-10 |
| BR112013014115A2 (pt) | 2019-09-24 |
| JP5941926B2 (ja) | 2016-06-29 |
| MX341118B (es) | 2016-08-09 |
| MX2013007316A (es) | 2013-07-29 |
| MX347298B (es) | 2017-04-21 |
| WO2012092373A3 (en) | 2013-10-24 |
| CA2816041A1 (en) | 2012-07-05 |
| AU2011352204A1 (en) | 2013-05-02 |
| KR20130136494A (ko) | 2013-12-12 |
| CN103491982B (zh) | 2017-09-12 |
| JP2014505685A (ja) | 2014-03-06 |
| EP2658579A2 (en) | 2013-11-06 |
| CN103491982A (zh) | 2014-01-01 |
| CL2015003580A1 (es) | 2016-07-15 |
| AU2011352204B2 (en) | 2015-05-21 |
| CA2816041C (en) | 2019-01-08 |
| EP2658579A4 (en) | 2015-07-22 |
| ZA201302896B (en) | 2014-07-25 |
| WO2012092373A2 (en) | 2012-07-05 |
| RU2619453C2 (ru) | 2017-05-16 |
| NZ611656A (en) | 2014-10-31 |
| CL2013001876A1 (es) | 2014-04-11 |
| SG189942A1 (en) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009123768A3 (en) | Nanocarrier and nanogel compositions | |
| MX2022008629A (es) | Nanoparticulas lipidicas para la administracion de farmacos in vivo, y usos de las mismas. | |
| Lächelt et al. | Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes | |
| NZ601737A (en) | Compositions for targeted delivery of sirna | |
| WO2009095479A3 (en) | Prodrug comprising a self-cleavable linker | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| IN2014DN00101A (enExample) | ||
| MX2021012934A (es) | Lipidos de amina ionizables y nanoparticulas lipidicas. | |
| PE20140180A1 (es) | SISTEMA DE ADMINISTRACION DE ARNip IN VIVO BASADO EN PEPTIDOS | |
| MX2011009808A (es) | Agentes de elaboracion de imagen optica. | |
| WO2007069068A3 (en) | Cell penetrating peptide conjugates for delivering nucleic acids into cells | |
| UA101497C2 (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| TN2012000417A1 (en) | Compounds as bradykinin b1 antagonists | |
| AR095081A1 (es) | Compuestos químicos | |
| AR082995A1 (es) | Profarmacos que comprenden un conjugado de conector de exendina | |
| NZ758049A (en) | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics | |
| CO6361910A2 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| BR112014002191A2 (pt) | amidas de ácido n-(tetrazol-5-il)- e n-(triazol-5-il)arilcarboxílico e seu uso como herbicidas | |
| BR112017012482A2 (pt) | copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero. | |
| MY156951A (en) | Micromirs | |
| EP4321177A3 (en) | Carbohydrate conjugates as delivery agents for oligonucleotides | |
| BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
| MX2012013375A (es) | Peptido c pegilado. | |
| HK1209045A1 (en) | Pegylated oxm variants | |
| EP2643009A4 (en) | COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |